These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 25212888)

  • 41. Role of reduced intensity conditioning in allogeneic hematopoietic cell transplantation for patients with multiple myeloma.
    Nishihori T; Kharfan-Dabaja MA; Ochoa-Bayona JL; Bazarbachi A; Pasquini M; Alsina M
    Hematol Oncol Stem Cell Ther; 2011; 4(1):1-9. PubMed ID: 21460601
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Autologous and allogeneic stem cell transplantation in follicular lymphoma.
    Van Besien K
    Transfus Apher Sci; 2005 Feb; 32(1):45-53. PubMed ID: 15737873
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term follow up of patients with multiple myeloma after high-dose chemotherapy and allogeneic stem cell transplantation.
    Rabitsch W; Prinz E; Ackermann J; Wöhrer S; Kaufmann H; Seidl S; Keil F; Kalhs P; Greinix H; Gisslinger H; Leitner G; Drach J
    Eur J Haematol; 2004 Jan; 72(1):26-31. PubMed ID: 14962259
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Yeshurun M; Labopin M; Blaise D; Cornelissen JJ; Sengeloev H; Vindelov L; Kuball J; Chevallier P; Craddock C; Socie G; Bilger K; Schouten HC; Fegueux N; Goker H; Maertens J; Bunjes D; Arnold R; Nagler A; Mohty M
    Cancer; 2014 Mar; 120(6):855-63. PubMed ID: 24338939
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and nonmalignant diseases: end of the beginning and future challenges.
    Satwani P; Harrison L; Morris E; Del Toro G; Cairo MS
    Biol Blood Marrow Transplant; 2005 Jun; 11(6):403-22. PubMed ID: 15931629
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Low-dose alemtuzumab vs. standard policy for prevention of graft-versus-host disease in unrelated and related allogeneic stem cell transplantation-a matched pair analysis.
    Busemann C; Neumann T; Schulze M; Klenner A; Thiele T; Greinacher A; Dölken G; Krüger WH
    Ann Hematol; 2013 Jul; 92(7):945-52. PubMed ID: 23463451
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advances in therapy of multiple myeloma.
    Bladé J; Rosiñol L
    Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tandem autologous-allogeneic nonmyeloablative sibling transplantation in relapsed follicular lymphoma leads to impressive progression-free survival with minimal toxicity.
    Cohen S; Kiss T; Lachance S; Roy DC; Sauvageau G; Busque L; Ahmad I; Roy J
    Biol Blood Marrow Transplant; 2012 Jun; 18(6):951-7. PubMed ID: 22155507
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
    Beaussant Y; Daguindau E; Pugin A; Mohty M; Avet-Loiseau H; Roos-Weil D; Michallet M; Chevalier P; Raus N; El-Cheikh J; Tabrizi R; Huyn A; Buzyn A; Socié G; Vincent L; Guilhot F; Yakoub-Agha I; Lenain P; François S; Beckerich F; Lioure B; Bulabois CE; Deconinck E;
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1452-9. PubMed ID: 25911579
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reduced intensity allogeneic stem cell transplantation in multiple myeloma.
    Bensinger WI
    Front Biosci; 2007 May; 12():4384-92. PubMed ID: 17485382
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Myeloablative allogeneic stem cell transplantation for advanced stage multiple myeloma: very long-term follow up of a single center experience.
    Kennedy GA; Butler J; Morton J; Hill G; Western R; Cummings J; Allison R; Durrant S
    Clin Lab Haematol; 2006 Jun; 28(3):189-97. PubMed ID: 16706936
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term outcomes following myeloablative allogeneic transplantation for multiple myeloma compared to autologous transplantation and the impact of graft-versus-myeloma effect.
    Khaled Y; Mellacheruvu S; Reddy P; Peres E; Mineishi S
    Bone Marrow Transplant; 2009 Sep; 44(5):325-6. PubMed ID: 19204708
    [No Abstract]   [Full Text] [Related]  

  • 53. Non-myeloablative conditioning and allogeneic transplantation for multiple myeloma.
    Osman K; Elliott B; Mandeli J; Scigliano E; Malone A; Isola L; Grosskreutz C
    Am J Hematol; 2010 Apr; 85(4):249-54. PubMed ID: 20162541
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Autologous-allogeneic tandem stem cell transplantation in patients with multiple myeloma.
    Kröger N
    Leuk Lymphoma; 2005 Jun; 46(6):813-21. PubMed ID: 16019525
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recent developments in hematopoietic stem cell transplantation for multiple myeloma.
    Bensinger WI
    Int J Hematol; 2003 Apr; 77(3):232-8. PubMed ID: 12731665
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed Hodgkin's disease following autologous stem cell transplantation.
    Ruiz-Argüelles GJ; López-Martínez B; López-Ariza B
    Arch Med Res; 2003; 34(3):242-5. PubMed ID: 14567405
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning--evidence for a superior outcome using melphalan combined with total body irradiation.
    Hunter HM; Peggs K; Powles R; Rahemtulla A; Mahendra P; Cavenagh J; Littlewood T; Potter M; Hunter A; Pagliuca A; Williams CD; Cook G; Towlson K; Marks David I; Russell NH;
    Br J Haematol; 2005 Feb; 128(4):496-502. PubMed ID: 15686458
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
    Resnick IB; Shapira MY; Slavin S
    Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma.
    Dingli D; Nowakowski GS; Dispenzieri A; Lacy MQ; Hayman S; Litzow MR; Gastineau DA; Gertz MA
    Clin Lymphoma Myeloma; 2006 Mar; 6(5):384-8. PubMed ID: 16640814
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.
    Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI;
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.